PIPELINE
| DRUG CANDIDATE | PROGRAM | TARGET | AREA | PLATFORM | DISCOVERY | PRECLINICAL | Phase I | Phase II |
| RS-0139 |  |
Integrin | Oncology | Sagitta® Bir | ||||
| RS-0337 | |
HER2 | Oncology | Sagitta® Dui | ||||
| RS-0461 | |
Integrin | Oncology | Sagitta® Dui | ||||
| RS-0625 | |
Integrin | Oncology | Sagitta® Bir | ||||
| RS-0735 | |
Undisclosed | Oncology | Sagitta® Bir | ||||
| DRUG | PROGRAM | TARGET | AREA | PLATFORM | PHASE |
|---|
| RS-0139 | RS Research | Integrin | Oncology | Sagitta® Bir | PhI Dose Escalation |
| RS-0337 | RS Research | HER2 | Oncology | Sagitta® Dui | Preclinical |
| RS-0461 | RS Research | Integrin | Oncology | Sagitta® Dui | Preclinical |
| RS-0625 | RS Research | Integrin | Oncology | Sagitta® Bir | Preclinical |
| RS-0735 | RS Research | Undisclosed | Oncology | Sagitta® Bir | Preclinical |
